Clinical and Translational Neuroscience (Aug 2021)

Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders

  • Giovanni B Frisoni,
  • Jean-Marie Annoni,
  • Stefanie Becker,
  • Tim Brockmann,
  • Markus Buerge,
  • Jean-François Démonet,
  • Dan Georgescu,
  • Anton Gietl,
  • Ulrich Hemmeter,
  • Stefan Klöppel,
  • Thomas Leyhe,
  • Andreas U Monsch,
  • Franco Rogantini,
  • Delphine Roulet Schwab,
  • Egemen Savaskan,
  • Karl Schaller,
  • Armin von Gunten,
  • Gabriel Gold

DOI
https://doi.org/10.3390/ctn5020014
Journal volume & issue
Vol. 5, no. 2
p. 14

Abstract

Read online

The present document represents the position of Swiss health-care associations, clinical and research centers, research-supporting foundations, and the association Alzheimer Switzerland regarding the care of persons with dementia and Alzheimer’s disease. We claim that dementia is not part of normal aging but a disease developing more frequently in old age; early diagnosis and treatment of dementia is paramount; all patients with dementia have the right to receive state-of-the-art treatments; more intense information, education, and counseling on dementia are necessary; media should provide balanced and fair reporting of scientific discoveries on Alzheimer’s and dementia; all patients with dementia have the right to be treated; anti-dementia drugs should be used and accompanied by listening, compassion, and understanding.

Keywords